32 completed, 5 recruiting, 5 unknown, 1 terminated. 43 Phase 2, 8 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 43 | Completed 32, Recruiting 5, Unknown 5, Terminated 1 |
| Phase 1 | 8 | Completed 5, Unknown 2, Recruiting 1 |
| Phase 3 | 2 | Completed 2 |
Follow Phosphorus Metabolism Disorders: new trials by email Literature Review of Phosphorus Metabolism Disorders trials Research Report on Phosphorus Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phosphate in Acute Pancreatitis Sodium Phosphate, Potassium Phosphate - Pancreatitis | Phase 2 | Recruiting | Duke University | 100 | 2026-07-09 | 2026-08-26 |
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID - Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis | Phase 2 | Recruiting | R1 Therapeutics | 168 | 2026-06-01 | 2026-08-26 |
| Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients Dipyridamole 75 MG - Hypophosphatemia, Kidney Transplantation | Phase 2 | Recruiting | Stanford University | 90 | 2025-05-15 | 2026-06-11 |
| Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia JMKX003002 will be administered orally, Sevelamer carbonate - Hyperphosphatemia | Phase 2 | Recruiting | Jemincare | 50 | 2024-12-30 | 2025-02-03 |
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia KK8123 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 39 | 2024-10-09 | 2026-11-06 |
| A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients AP-306, Sevelamer Carbonate - Chronic Kidney Diseases, Hyperphosphatemia | Phase 2 | Completed | Alebund Pharmaceuticals | 55 | 2023-02-20 | 2024-01-10 |
| To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG, Placebo - Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | Grand Life Science (Liaoning) Co., Ltd. | 48 | 2020-10-21 | 2021-07-28 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients VS-505, Sevelamer Carbonate - Hyperphosphatemia | Phase 2 | Completed | Shanghai Alebund Pharmaceuticals Limited | 158 | 2020-10-13 | 2022-10-18 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age Burosumab - X-linked Hypophosphatemia (XLH) | Phase 1 / Phase 2 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 16 | 2020-02-26 | 2024-11-07 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebp - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 47 | 2019-04-29 | 2024-03-07 |
| Dose-finding Study of KHK7791 in Hyperphosphatemia Patients KHK7791, Placebo - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 207 | 2019-04-15 | 2024-03-07 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| BGJ398 for the Treatment of Tumor-Induced Osteomalacia BGJ398 - Tumor-Induced Osteomalacia, Oncogenic Osteomalacia | Phase 2 | Terminated | National Institute of Dental and Craniofacial Research (NIDCR) | 4 | 2019-02-27 | 2026-11-10 |
| A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD KHK7791 - Hyperphosphatemia | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 67 | 2018-12-27 | 2024-03-07 |
| Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Burosumab - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 13 | 2016-05-05 | 2024-05-06 |
| A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis VS-505 - End Stage Renal Disease, Hyperphosphatemia | Phase 1 / Phase 2 | Unknown | KDL Inc. | 30 | 2015-06-01 | 2016-02-08 |
| Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) KRN23 - X-Linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 20 | 2015-01-30 | 2024-05-06 |
| Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) burosumab - X-linked Hypophosphatemia | Phase 2 | Completed | Kyowa Kirin, Inc. | 52 | 2014-07-02 | 2024-05-06 |
| Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease PT20, Placebo - Hyperphosphataemia | Phase 2 | Completed | Phosphate Therapeutics | 153 | 2014-05-07 | 2018-01-16 |
| Dose Finding Study to Treat High Phosphate Levels in the Blood. AZD1722, Placebo - Hyperphosphatemia | Phase 2 | Completed | Ardelyx | 162 | 2014-03-01 | 2020-09-14 |
Showing 20 of 43. Sign in to see all of them.
Hyperphosphatemia (32) · Renal Insufficiency, Chronic (11) · Familial Hypophosphatemic Rickets (8) · Kidney Failure, Chronic (8) · Hypophosphatemia (5) · Kidney Diseases (4) · Renal Insufficiency (2) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Bronchiolitis Obliterans Syndrome (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Inflammation (1) · Metabolic Diseases (1) · Musculoskeletal Diseases (1) · Oncogenic osteomalacia (1)
Nutritional and Metabolic Diseases (43) · Metabolic Diseases (42) · Female Urogenital Diseases and Pregnancy Complications (28) · Urogenital Diseases (28) · Female Urogenital Diseases (27) · Male Urogenital Diseases (27) · Urologic Diseases (27) · Kidney Diseases (23) · Disease Attributes (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Chronic Disease (18) · Renal Insufficiency (16) · Avitaminosis (9)
Sevelamer (10) · burosumab (6) · lanthanum carbonate (4) · tenapanor (3) · Calcium Carbonate (2) · Niacinamide (2) · SBR 759 (2) · ferric citrate (2) · iron-magnesium hydroxycarbonate (2) · potassium phosphate (2) · BID protein, human (1) · Dipyridamole (1) · Geritol (1) · Growth Hormone (1) · Iron (1)
Kyowa Kirin Co., Ltd. (6) · Kyowa Kirin, Inc. (3) · Ardelyx (2) · Bayer (2) · Genzyme, a Sanofi Company (2) · Ineos Healthcare Limited (2) · KDL Inc. (2) · Novartis Pharmaceuticals (2) · Alebund Pharmaceuticals (1) · Astellas Pharma Inc (1) · Bicetre Hospital (1) · Duke University (1) · Fresenius Medical Care Deutschland GmbH (1) · Grand Life Science (Liaoning) Co., Ltd. (1) · Ilypsa (1)
United States (21) · Japan (9) · United Kingdom (7) · Germany (6) · China (5) · France (5) · Canada (4) · Poland (3) · Australia (2) · Italy (2) · Puerto Rico (2) · Spain (2) · Sweden (2) · Argentina (1) · Austria (1)
Amy Zhang, PhD (2) · Alan H Lau, Pharm.D. (1) · Alex Mullen (1) · Daniel O Young, MD (1) · David P Rosenbaum, PhD (1) · Geoff Block, MD (1) · Geoffrey A Block, MD (1) · Guido Smeets, MD (1) · Johan Rosman, MD, Ph.D (1) · Julia B Lewis, MD (1)
PMID 40576086, PMID 21854503, PMID 25919461, PMID 32721016, PMID 38323855, PMID 39151033, PMID 19776051, PMID 21426511, PMID 24968790, PMID 24975892, PMID 26073451, PMID 28822957, PMID 29617976, PMID 29791829, PMID 30638856, PMID 32651955, PMID 33766811, PMID 34636899, PMID 35236302, PMID 36072994, PMID 38453435, PMID 42044650
2009 (1), R01DK142980 (1)